Centre National De La Recherche Scientifique

Institut Pasteur

Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Institut Pasteur Du Cambodge

Universite Paris 7

Institut Curie

Université Paris Diderot-paris 7

Institute Pasteur

Themis Bioscience Gmbh

Invectys Sas

Ministère Des Armées—direction Centrale Du Service De Sante Des Armée

Université Paris 7—denis Diderot

Universite Paris Vii

Frédéric Tangy

Chantal Combredet

Philippe Despres

Pierre Charneau

Marie-Pascale Frenkiel

Marc Gregoire

Clarisse Lorin

Lucile Mollet

Marianne Lucas-Hourani

Yves Jacob

Hugues Bedouelle

Erika Navarro-Sanchez

Frederic Delebecque

Etienne Simon-Loriere

Jean-François Fonteneau

Jean-Baptiste Guillerme

Jean-Claude Manuguerra

Claude Roth

Nicolas Escriou

Sylvie Van Der Werf

Valérie Labrousse-Najburg

Michel Brahic

Valérie Lorin

Anne Gauvrit

Philippe Buchy

Marie Pascale Frenkiel

Bernadette Crescenzo-Chaigne

Benoît Callendret

Jean-Michel Betton

Sylvie Gerbaud

Ana Maria Burguiere

Saliha Azebi

Jean-François Delagneau

Monique Martin

Chaouki Miled

Pierre Langlade Demoyen

Sylvain Baize

André Habel

Anavaj Sakuntabhai

Elodie Pliquet

Daniel Dauzonne

Frederik Kunst

Nicolas Robert Xavier Escriou

Ho Hong Hai Vo

Samantha Brandler

Andre Habel

Pierre-Olivier Vidalain

Hélène Munier-Lehmann

Frédéric Delebecque

Anastassia Komarova

Marie Mura

Anavaj Shakuntabai

Monica Sala

Daria Jacob

Frederick Kunst

Mathieu Mateo

Frederik Inst Pasteur Bureau Des Brevets Et Inventions Kunst

Jean-Francois Fonteneau

Valerie Labrousse-Najburg

Valérie Labrousse Najburg

Philippe Després

Frederik Institut Pasteur Kunst

The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.

Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions

The invention relates to recombinant measles virus expressing Lassa virus polypeptides, and concerns in particular immunogenic LASV particles expressed by a measles virus and/or virus like particles (VLPs) that contain proteins of a Lassa virus. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acid constructs, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Lassa virus.

Lassa vaccine

The present invention relates to recombinant measles virus expressing Zika virus proteins and their applications, in particular in inducing preventive protection against Zika virus. The present invention is directed to recombinant measles virus (MV) expressing at least (i) the precursor of membrane (prM) protein of a Zika virus (ZIKV), and the envelope (E) protein of a ZIKV or a truncated version thereof, or (ii) the E protein of a ZIKV or a truncated version thereof, and concerns recombinant infectious particles of said MV-ZIKV able to replicate in a host after an administration, and also Virus Like Particles (VLPs) that contain these ZIKV proteins at their surface. The present invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles and VLPs. The present invention also relates to the use of these recombinant infectious particles and/or VLPs, in particular under the form of a composition, more particularly in a vaccine formulation, for the prevention of an infection by ZIKV or for the preventive protection against clinical outcomes of ZIKV infection.

Recombinant measles virus expressing zika virus prM and E proteins

The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.

Recombinant measles vaccine expressing hTERT

The invention relates to an active ingredient which is a live attenuated recombinant measles virus expressing influenza A virus antigen(s) and to its use in the elicitation of immunity, in particular protective immunity and advantageously broad-spectrum protective immunity against influenza A virus. In particular, the influenza A virus is selected among epidemic seasonal viruses and/or endemic viruses circulating in the human population and advantageously encompasses a pandemic virus such as H1N1v.

Live recombinant measles-M2 virus&#x2014;its use in eliciting immunity against influenza viruses

The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.

Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5' copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5&#x2032; copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases

The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment.

Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy

Recombinant measles viruses expressing epitopes of antigens of RNA viruses&#x2014;use for the preparation of vaccine compositions

The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.

The present invention relates to a subunit vaccine platform based on multimeric ribonucleoproteins (RNPs) comprising nucleoproteins of a non-segmented negative-strand ribonucleic acid (RNA) virus as carriers of heterologous polypeptides. The present invention also relates to multimeric RNPs resulting from the assembly of at least 200 fusion proteins with a cellular RNA, or to recombinant yeasts or yeast lysates expressing these multimeric RNPs. It also concerns a process for the preparation of these multimeric RNPs or recombinant yeasts or yeast lysates. In particular, the present invention relates to their use as active ingredient for the in vitro production of an immunogenic composition or in eliciting a protective prophylactic or a therapeutic immune response against said heterologous polypeptide in a host in need thereof. Recombinant yeasts or yeast lysates of the invention can also be used as expression and vector systems for delivery to a host.

Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides

The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.

Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection

Growing community of inventors

Les Lilas, France

Frédéric Tangy